Cargando…

Methylene blue inhibits replication of SARS-CoV-2 in vitro

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. Currently there is no antiviral treatment recommended against SARS-CoV-2. Identifying effective antiviral drugs is urgently requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gendrot, Mathieu, Andreani, Julien, Duflot, Isabelle, Boxberger, Manon, Le Bideau, Marion, Mosnier, Joel, Jardot, Priscilla, Fonta, Isabelle, Rolland, Clara, Bogreau, Hervé, Hutter, Sébastien, La Scola, Bernard, Pradines, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566888/
https://www.ncbi.nlm.nih.gov/pubmed/33075512
http://dx.doi.org/10.1016/j.ijantimicag.2020.106202
Descripción
Sumario:In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. Currently there is no antiviral treatment recommended against SARS-CoV-2. Identifying effective antiviral drugs is urgently required. Methylene blue has already demonstrated in vitro antiviral activity in photodynamic therapy as well as antibacterial, antifungal and antiparasitic activities in non-photodynamic assays. In this study. non-photoactivated methylene blue showed in vitro activity at very low micromolar range with an EC(50) (median effective concentration) of 0.30 ± 0.03 μM and an EC(90) (90% effective concentration) of 0.75 ± 0.21 μM at a multiplicity of infection (MOI) of 0.25 against SARS-CoV-2 (strain IHUMI-3). The EC(50) and EC(90) values for methylene blue are lower than those obtained for hydroxychloroquine (1.5 μM and 3.0 μM) and azithromycin (20.1 μM and 41.9 μM). The ratios C(max)/EC(50) and C(max)/EC(90) in blood for methylene blue were estimated at 10.1 and 4.0, respectively, following oral administration and 33.3 and 13.3 following intravenous administration. Methylene blue EC(50) and EC(90) values are consistent with concentrations observed in human blood. We propose that methylene blue is a promising drug for treatment of COVID-19. In vivo evaluation in animal experimental models is now required to confirm its antiviral effects on SARS-CoV-2. The potential interest of methylene blue to treat COVID-19 needs to be confirmed by prospective comparative clinical studies.